1. Prof. Dr. Hanno Wild Bayer Schering Pharma AG Head of Global Lead Generation & Optimization Basle, October 08, 2009 Successful innovation within a post-merger environment
2.
3.
4. Bayer Schering Pharma* Key Data Specialty Medicine Diagnostic Imaging General Medicine Women’s Healthcare * USA/Canada: Bayer HealthCare Pharmaceuticals Among the top 10 specialty pharma companies worldwide Focus on 4 major business units Sales 2008: EUR10,704 million Investments in R&D: mid term 15 – 17 % of total net sales
5. Bayer Schering Pharma’s R&D strategy Key factors to increase Productivity 4 therapeutic research areas with activities from target discovery up to launch (reduced from 8) 1 … more focus: Increase in development candidate output at decreased cost per NME (global use of platforms, stringent resource allocation, site consolidation) 2 … higher efficiency: Common mechanism approach to utilize opportunities 4 … value maximization: NME: New Molecular Entity Proof-of-Concept approach and strict project progression criteria 3 … better quality:
6. Bayer Schering Pharma’s R&D Strategy Focus on Four Therapeutic Research Areas Bayer Schering June 2005 Oncology Cardiology Hematology Oncology Gynecology Immunology Dermatology Andrology Diagnostic Imaging Bayer Schering Pharma June 2007 Cardiology Diagnostic Imaging Women’s Healthcare Oncology June 1999 Bayer Schering Oncology Cardiology Hematology Oncology Gynecology, FC MM Immunology/Inflam. Dermatology Andrology Cardiology Diabetes/Obesity COPD/Asthma Gene Therapy Diagnostic Imaging
7.
8. Bayer Schering Pharma’s R&D Pipeline A balanced mix of NME and LCM opportunities Status as of July 2009 Phase II (17) Phase III (18) Medical ill Xarelto ® SPAF Xarelto ® VTE Treatment Xarelto ® wet AMD VEGF Trap-Eye CRVO VEGF Trap-Eye PAH Riociguat (sGC Stimulator) CTEPH Riociguat (sGC Stimulator) ACS Xarelto ® Acute Heart Failure Cinaciguat (sGC Activator) DME VEGF Trap-Eye PH in COPD / ILD Riociguat (sGC Stimulator) 2nd line Breast Cancer Lonaprisan (ZK-PRA) Lung / Ovar / Prostate Sagopilone (ZK-EPO) Alzheimer PET Imaging BAY94-9172 (AV1 / ZK) Cancer DAST Inh. (BAY73-4506) Liposomal Formulation Kogenate ® Breast Cancer Nexavar ® Ovarian or Peritoneal Cancer Nexavar ® Colorectal Cancer Nexavar ® Additional Indications Nexavar ® Lung Infection Cipro ® inhale Oral Contraception E2+DRSP Oral Contraception OC+DHEA Oral Contraception Valette plus Gram-neg. Pneumonia Amikacin inhale NSCLC Nexavar ® Multiple Sclerosis Alemtuzumab Bone Met. Prev. Breast Cancer Bonefos ® Dysmenorrhea (J) YAZ ® Oral Contraception YAZ ® Flex Oral Contraception Yasmin ® plus / YAZ ® plus Menopause Management Angeliq low-low Contraception LCS (ULD LNG) ACS Aspirin ® i.v. Contraception FC Patch Low Phase I (8) PH in COPD Elastase Inhibitor Cancer L19-SIP Colorectal Cancer L19-TNFalpha Gastro IBD Lipoxin Cancer MN Immunoconjugate Cancer PI3K Inhibitor Cancer MEK- Inhibitor Hemophilia rec. Factor VII Despite the challenges to R&D, Bayer Schering Pharma brought a constant flow of NMEs to the market while reducing its cost basis New Molecular Entities (NME) Life Cycle Management (LCM)
9.
10.
11. Forward-Looking Statements This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
![Challenges for the entire pharmaceutical industry Unprecedented change around the globe ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Environmental Pressures ,[object Object],[object Object],[object Object],[object Object],[object Object],Industry Challenges ,[object Object],[object Object],[object Object],[object Object],[object Object],Challenges for R&D](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)